Altogether, these data suggest the STK11/LKB1 mutation as a major driver of immune-escape and that co-occurring KRAS/LKB1 mutation may be a potential biomarker for limited clinical benefits achieved by ICIs in advanced NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.